Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

In addition to leading Open Medicine Foundation’s research team, Ronald W. Davis, PhD, is a professor of Biochemistry and Genetics. He is also the director of the Stanford Genome Technology Center. Dr. Davis’s current mission is to discover the cause(s) of, a molecular-based diagnostic test for, and a cure for ME / CFS.

By developing new technologies, Dr. Davis does cutting-edge and interdisciplinary research into cancer, immunology, genetics, infectious disease, novel drug development, and nanofabrication of diagnostic instrumentation. Most notably, in 2013, he was named one of the top 9 of today’s greatest inventors in The Atlantic magazine.

In trying to understand ME / CFS, he has read the literature, consulted with leading specialists, attended scientific meetings, and thought extensively about how he could apply his expertise to finding a molecular-based diagnostic test, treatment, and cure. His expertise and reputation make him an optimally qualified scientist to take on ME / CFS.

Although primarily a biochemist by training, Davis has used his deep understanding of biochemical and physical chemical principles to address problems of fundamental importance to genetics. His contributions to the field are numerous and profound. He created, for example, some of the earliest phage lambda-based cloning vectors (DNA molecules that carry foreign DNA into a host cell, where the foreign DNA can then be replicated.)

Working on the genome and biology of the Saccaharomyces cerevisiae (baker’s yeast), his lab developed the first artificially constructed chromosomes, which are now routinely used to clone large genes and map complex genomes. In 1977, Davis co-authored a landmark paper that described the very first case of what is now known as genome editing, the ability to replace any nucleotide in the yeast genome with any other nucleotide.
Ron Davis smiling and tall
In 1980, in another landmark paper—one of the most highly cited in the field of human genetics—Davis and his team described how sequence variants in the genomes of humans and other species could provide genetic markers for making a genetic and physical map of the human genome. That paper helped launch the field of genomics. A few years later, Davis’ lab showed how DNA libraries could be searched with protein-finding antibodies, a technique that has made it possible for scientists to identify genes for important proteins, including in humans.

During the 1990s, Davis contributed to the development of the very first microarrays, tools that enable scientists to analyze the gene expression of thousands of genes simultaneously. He then went on to help standardize this technology, paving the way for other scientists to use it for clinical applications.

In recent years, his lab has produced sequences of several yeast chromosomes: part of the Escherichia coli genome, part of the arabidopsis thalialiana genome (arabidopsis is a plant widely used in the study of genetics), part of the human genome, and part of the genome of Plasmodium falciparum (a parasite that causes malaria in humans). Dr. Davis also continues to develop new biotechnologies, including DNA nanotechnology.

Dr. Davis taught a course in Bacterial Genetics at Cold Spring Harbor from 1976 to 1981 and wrote the first manual on genetic engineering techniques (published by the Cold Spring Harbor press). He has also served on the National Institutes of Health (NIH) Genome Research Review Committee, the NIH Center for Biomedical Ethics Steering Committee, The World Health Organization Immunology of Tuberculosis Steering Committee, and as chairman of the WHO Strategic Research Steering Committee.

Davis has been the recipient of many professional honors, including memberships in the National Academy of Sciences, the American Academy of Microbiology, and the Human Genome Organization. Other honors include the Dickson Prize in Medicine from the University of Pittsburgh (2005), the Lifetime Achievement Award from the Genetics Society of America (2004), the Chiron Corporation Biotechnology Research Award (1998), the Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research (1992), the Eli Lilly Award in Microbiology and Immunology (1976), and the United States Steel Award presented by the National Academy of Sciences (1981).

2013 Warren Alpert Foundation Prize
2011 Gruber Genetics Prize

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo